Skip to content

Comparison of different doses of tranexamic acid in hemostasis after posterior lumbar surgery

Comparison of different doses of tranexamic acid in hemostasis after posterior lumbar surgery

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026582
Enrollment
Unknown
Registered
2019-10-15
Start date
2019-10-14
Completion date
Unknown
Last updated
2019-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar disease

Interventions

A:high dose tranexamic acid
B:middle dose tranexamic acid
C:low dose tranexamic acid

Sponsors

Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The patient was clearly diagnosed as lumbar disc herniation, lumbar spinal stenosis or lumbar spondylolisthesis, and received regular conservative treatment for 3 months, with no significant relief of symptoms.Patients were proposed to undergo posterior lumbar decompression and fusion. 2. Aged 18-80 years. 3. ASA I- III. 4. Patients volunteered to participate in this study and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. patients with allergy to TXA; 2. patients with previous history of coagulation dysfunction, thrombotic disease, or preoperative diagnosis of deep vein thrombosis by venous ultrasonography or angiography; 3. patients with severe damage to vital organs and difficult to cooperate with orthopedic treatment; 4. PLT 160/90mmhg); 7. ASA)> III 8. BMI>30kg/m2; 9. severe osteoporosis; 10. pregnant women or patients with severe mental illness; 11. take nsaids within one week before surgery.

Design outcomes

Primary

MeasureTime frame
length of operation;intraoperative blood loss;Postoperative drainage;Volumes of infused blood;Complications and adverse events;

Countries

China

Contacts

Public ContactFeng Shuo

Affiliated Hospital of Xuzhou Medical University

781733181@qq.com+86 18552880088

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026